Table 1.

Summary of baseline characteristics for patients with appendiceal adenocarcinomas

^aGrade: 1–well-differentiated; 2–moderately differentiated; 3–poorly differentiated.

^bStage: I/II/III–nonmetastatic disease; IVA–well-differentiated intraperitoneal metastatic disease; IVB/IVC–moderate to poorly differentiated metastatic disease.

^cCCS: 0/1–disease <2.5 mm; 2/3–disease >2.5 mm.

^dCOX-2: COX-2 expression was assessed using immunohistochemistry.

^eKRAS: KRAS mutation was assessed using polymerase chain reaction-based DNA sequencing.

Abbreviations: CCS, completeness of cytoreduction score; COX-2, cyclooxygenase-2 expression.